Concurrent Sessions
Monday, April 7 – 1100-1230 |
Click on the title to view the abstract |
Concurrent Session 1 –
Oral Presentations
From Evidence to
Decision
Health Technology Assessment in the
Context of Complimentary and Overlapping Technologies: A Case Study
Presenting Author: Dr. John Walker, School Of Public Health,
University Of Alberta.
Where Do HTA Results Fit in the
Determination of the Optimal Use of Drugs and Health Technologies?
Presenting Author: François Dionne, University of British Columbia
Stakeholders’ Development of
Criteria for Technology Evaluation and Prioritization at the Local Level
Presenting Author: Dr. Paule Poulin, Calgary Health Region
Concurrent Session 2 –
Oral Presentations
Safety and
Effectiveness
Right Person, Right Drug, Right
Dose: The Impossible Dream?
Presenting Authors: Catherine Street and Astrid Perrot-Daley,
Memorial University.
Improving Response of Decision
Makers to Guidance that an Interventional Procedure is Safe and Efficacious
Presenting Author: Tania Lourenco, Health Services
Research Unit, University
Of Aberdeen.
An Analysis of the Impact of
Variations in Bleeding Definitions on Study Results in Patients Receiving
Antithrombotic Agents
Presenting Author: Dr. Carla Frye, EPI-Q, Inc.
Concurrent Session 3 –
Oral Presentations
The Role of Patients
and the Public
Engaging Patients in Canada
in HTA: What is Working and What Needs to be Done
Presenting Authors: Dr. Durhane Wong-Rieger, Consumer
Advocare Network; Professor Wayne Taylor, DeGroote
School of Business, McMaster University;
Elizabeth Fowler, World Health Advocacy.
Improving Public Understanding of
Public Drug Purchasing Decisions through Brokered Dialogue
Presenting Authors: Dr. Jim Lavery and Dr. Janet
Parsons, Li Ka Shing Knowledge Institute of St.
Michael's Hospital.
Concurrent Session 4 - Panel Discussion
The Emerging Role of
Post-market Evidence Generation in Decision making ― Are We Ready? -
Dr. Maurica Maher
The Emerging Role of
Post-market Evidence Generation in Decision making ― Are We Ready? - Cynthia Sunstrum
Presenting Authors: Dr. Judith
Glennie, Janssen-Ortho
Inc.; Dr. Maurica Maher and Cynthia Sunstrum, Health Canada.
Concurrent Session 5 – Panel Discussion
How Do We Get the Most from HTA? - Dr. Stephen Bornstein
How Do We Get the Most from HTA? - Don Husereau
How Do We Get the Most from HTA? - Dr. Maurice McGregor
Presenters: Dr. Stephen Bornstein, NL Centre for Applied
Health Research; Don Husereau,
Canadian Agency for Drugs and Technologies in Health; Dr. Maurice McGregor,
McGill University Health Centre
Monday, April 6 – 1530-1700
Concurrent Session 6 –
Oral Presentations
Oncology: Evidence and
Issues
From Concept, to Evidence, to
Implementation: British Columbia’s New Colorectal Cancer Screening Program
Presenting Author: Bruce Brady, British Columbia
Ministry of Health Services.
Evidence and Values: Requirements
for Public Reimbursement of Drugs for Rare Diseases — A Case Study in Oncology
Presenting Author: Dr. Stuart MacLeod, Child & Family Research Institute.
Assessment of Liquid-Based Cytology
for Screening Pre-Cancerous Cervical Cells: Experience of Two Teaching
Hospitals
Presenting
Author: Dr. Alain Lapointe, Centre Hospitalier de L'Université de Montréal.
Concurrent Session 7 –
Oral Presentations
New Approaches
Beating the Evidence Game: The
Direct-to-Consumer Marketing of Stem Cell Therapies
Presenting Author: Ubaka Ogbogu, University of Toronto,
Faculty of Law.
Perspectives on NICE’s
Recommendations to Use Health Technologies Only in the Context of Appropriate
Evidence Development
Presenting Author: Dr. Sarah Garner, National
Institute for Health and Clinical Excellence (NICE).
Incorporating Science and Technology
Studies Perspectives: Moving Health Technology Assessment Forward
Presenting Author: Julie Alati-it, University
Of Calgary.
The SPIRIT Initiative: Defining
Standard Protocol Items for Randomized Trials
Presenting Author: Dr. An-Wen Chan, Mayo Clinic.
Concurrent Session 8 –
Oral Presentations
Pharmaceutical Issues
Five Years of CEDAC Recommendations:
An Evidence Base for Expectations?
Presenting Author: Angela Rocchi, Axia Research.
Global Trends in Drug Pricing and Reimbursement
Presenting Author: Wayne Critchley, Canadian Agency for Drugs and Technologies in Health.
Indirect Comparisons in Economic
Evaluations: Experience from the Common Drug Review
Presenting Authors: Julie Blouin and Karen Lee, Canadian Agency for Drugs and
Technologies in Health.
Concurrent Session 9 – Panel Discussion
Embedding Clinical
Practice Guidelines into the Mosaic of Care: Engaging KeyStakeholders in
Guideline Development and Dissemination
Presenting Authors: Christa Harstall, Institute of
Health Economics; Dr. Paul Taenzer, Calgary Health Region Chronic Pain Centre;
Donna Angus, Alberta Heritage Foundation for Medical Research; Darlene
Schindel, Alberta Bone and Joint Health Institute; Barry Ulmer, Chronic Pain
Association of Canada.
Concurrent Session 10 – Panel Discussion
Better Alignment
between Producers and Users of Drugs and Health Technologies - Dave Ames
Better Alignment
between Producers and Users of Drugs and Health Technologies - Ivan VranaBetter Alignment
between Producers and Users of Drugs and Health Technologies - Philip Schwab
Better Alignment
between Producers and Users of Drugs and Health Technologies - Jean Pruneau
Better Alignment
between Producers and Users of Drugs and Health Technologies - Bob Nakagawa
Presenters: Dave Ames, MEDEC; Ivan Vrana, Rx&D; Philip Schwab, BIOTECanada; Jean Pruneau, Health Canada; Bob Nakagawa, BC Ministry of Health; Bob Main, Industry Canada
Tuesday, April 7 – 1030-1200
Concurrent Session 11
– Oral Presentations
Evidence Uptake and
Use
Improving the Uptake of HTAs within a
Regional Health Authority
Presenting Author: Dr. Roger Chafe, Cancer Care Ontario.
The Epidemiology and Quality of
Systematic Reviews of Health Professional Behaviour Change Interventions
Presenting Author: Michelle Weir, Cochrane Effective
Practice and Organisation of Care Group.
How do CME Speakers Use Research
Results to Support Therapeutic Recommendations? A Quantitative and Qualitative
Study
Presenting Author: Dr. Michael Allen, Continuing
Medical Education, Dalhousie
University.
Concurrent Session 12 – Oral Presentations
Budget Creep: An Overlooked Factor in the Sustainability Debate
Presenting Author: Dr. Maurice McGregor, McGill University
Health Centre
Funding Non-formulary Medications:
Do We or Don’t We?
Presenting Author: Janet Templeton, Eastern Health Regional Health
Authority, Newfoundland and Labrador.
L’évaluation
des technologies et des modes d’intervention en santé (ETMIS) dans les hopitaux
: est-ce possible ? - pt 2 - Chantale Simard
Presenting Authors : Chantale Simard and Dr. Marc
Rhainds, Centre Hospitalier Universitaire de Québec.
Concurrent Session 13
– Oral Presentations
HTA, Evidence, and Disease Management
Diagnosis and Behavioural
Interventions for Autism: An Assessment of Guidelines and Systematic Reviews to
Meet the Needs of Provincial Decision Makers
Presenting Authors: Lynda McGahan and Brendalynn Ens, Canadian Agency for Drugs and
Technologies in Health.
Use of Diagnostic (CT) and
Pharmaceutical (tPA) Technologies for Acute Stroke: Are We Closing the Gap?
Presenting Authors: Elizabeth Woodbury, Canadian
Stroke Strategy; Dr. Patrice Lindsay, Canadian Stroke Network.
Home Telehealth for Chronic Disease
Management
Presenting Author: Julie
Polisena, Canadian Agency for Drugs and Technologies in
Health.
Concurrent Session 14 – Panel Discussion
Different Drugs, Different Thresholds: A Social Good?
Different Drugs,
Different Thresholds: A Social Good? - Scott Gavura
Different Drugs,
Different Thresholds: A Social Good? - Dr. Gerald Evans
Different Drugs,
Different Thresholds: A Social Good? - Bob Nakagawa
Different Drugs,
Different Thresholds: A Social Good? - Denis Morrice
Different Drugs,
Different Thresholds: A Social Good? - Betsy Miller
Presenters: Scott Gavura, Cancer Care Ontario; Dr. Gerald Evans, Ontario Ministry of Health and Long-Term Care; Bob Nakagawa, British Columbia Ministry of Health; Denis Morrice, Ontario Rheumatology Association; Betsy Miller, Axia Research.
Concurrent Session 15 – Panel Discussion
Increased
Collaboration in Drug Reviews Along the Market Access Continuum – Initial Steps
and What Next? - Barbara Jaszewski
Increased
Collaboration in Drug Reviews Along the Market Access Continuum – Initial Steps
and What Next? - Dr. Eric Lun
Increased
Collaboration in Drug Reviews Along the Market Access Continuum – Initial Steps
and What Next? - Sandy Pagotto
Increased
Collaboration in Drug Reviews Along the Market Access Continuum – Initial Steps
and What Next? - Dr. Robert Peterson
Increased
Collaboration in Drug Reviews Along the Market Access Continuum – Initial Steps
and What Next? - Stephen Kravcik
Increased
Collaboration in Drug Reviews Along the Market Access Continuum – Initial Steps
and What Next? - Linda Wilheim
Presenting Authors: Barbara Jaszewski, Bayer Healthcare; Dr. Eric Lun, BC Ministry of Health Services; Sandy Pagotto, Canadian Agency for Drugs and Technologies in Health; Dr. Robert Peterson, Chair, Canadian Expert Drug Advisory Committee (CEDAC); David Lee, Health Canada; Stephen Kravcik, Ottawa Hospital; Linda Wilhelm, Best Medicines Coalition.